Search

You searched for "Glasgow"

85 results found

In conversation with Roger Kirby

3 September 2020 | URO - Core Urology
We were delighted to catch up with Roger Kirby, new President of the RSM, about his illustrious career in urology. Can you tell us a little bit about what led you into the field of urology and what have been...

The role of embolisation in urology

3 September 2024 | | URO - Functional / Reconstructive Urology, URO - Urologic Oncology
Case 1 An 86–year–old male presented with visible haematuria and suprapubic pain. He had a history of diabetes, heart failure, benign prostatic hypertrophy, aortic valve replacement, deep vein thrombosis (DVT) and atrial fibrillation (AF) and was anticoagulated on a non-VKA...

Neuroendocrine bladder tumour

5 February 2025 | | URO - Urologic Oncology
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...

History of prostate biopsy – part 2

1 September 2018 | | URO - Basic Science Research, URO - Urologic Oncology, URO - Technology
For Part 1 of this topic is available here. The major limitations of the transrectal ultrasound (TRUS) guided prostate biopsy (PBx) protocols are the risk of profound sepsis and the risk of persistently significant false negative rates, related to the...

Men with a susceptibility to prostate cancer: implications of family history in PCa risk-prediction

3 September 2021 | | URO - Urologic Oncology
Incorporation of family history (FH) status into prostate cancer (PCa) risk stratification has the potential to underpin many aspects of PCa care. This group of men presents a unique challenge in early cancer detection, particularly given that most men without...

The doctor as the patient: receiving bad news

13 March 2023 | URO - Urologic Oncology
This article, written by a GP working in the NHS, gives a unique insight into the experience of being a urology patient and some thoughtful advice on ‘breaking bad news’. Day 1 Alarm bells ring. It’s spotting an email from...

Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer

1 January 2016 | | URO - Urologic Oncology, URO - Technology
The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...

The role of transperineal template biopsies in the diagnosis of prostate cancer

1 March 2014 | | URO - Urologic Oncology
The case In 2002, Mr A, a 64-year-old software engineer, was referred by his GP for further investigation of a raised prostate specific antigen (PSA) of 6.2. His prostate felt benign. He underwent transrectal ultrasound guided (TRUS) prostate biopsies. This...

Can dogs smell prostate cancer?

4 March 2025 | | URO - Urologic Oncology
For centuries we have known that man’s best friend has an exceptional sense of smell. ‘Sniffer’ dogs are found in a wide range of roles, including drug and explosive detection as part of airport security, helping emergency services locate survivors...

Prostate cancer in men of African heritage: understanding the risk and prognostic factors

2 July 2025 | | URO - Urologic Oncology
Prostate cancer (PCa) represents a major public health concern and is recognised as one of the most common cancers worldwide, accounting for a significant proportion of cancer-related deaths. It is the second most common malignancy among men globally after lung...

Uroscopy

1 September 2017 | URO - Technology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). You may feel somewhat distanced from the medical practitioners of mediaeval Florence but...

The role of PET-CT imaging in prostate cancer

4 October 2021 | | URO - Urologic Oncology
Prostate cancer (PCa) is the second most common cancer in the UK, with 43,000 cases in 2017-18 [1,2]. Accurate primary staging and the detection of suspected recurrence following treatment is vital for directing management and predicting prognosis. This has conventionally...